Generic Focinvez Availability
Last updated on Nov 6, 2024.
Focinvez is a brand name of fosaprepitant, approved by the FDA in the following formulation(s):
FOCINVEZ (fosaprepitant dimeglumine - solution;intravenous)
-
Manufacturer: STERISCIENCE
Approval date: August 22, 2023
Strength(s): EQ 150MG BASE/50ML (EQ 3MG BASE/ML) [RLD]
Has a generic version of Focinvez been approved?
No. There is currently no therapeutically equivalent version of Focinvez available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Focinvez. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Compositions of fosaprepitant and methods of preparation
Patent 11,065,265
Issued: July 20, 2021
Inventor(s): Yu Jianwei & Wang Yulu
Assignee(s): SPES PHARMACEUTICALS INC.The present application and its embodiments teach stable compositions of fosaprepitant or a pharmaceutically acceptable salt thereof with such compositions lacking polysorbate 80 and containing dual functional excipients of hydrolysis inhibition and solubility enhancement. Further described are methods of preparation of such compositions. Among other advantages of contemplated compositions, fosaprepitant hydrolysis degradation is kept low and the compositions maintain physically and chemically stable for prolonged period.
Patent expiration dates:
- January 11, 2039✓
- January 11, 2039
-
Patent 12,042,504
Patent expiration dates:
- January 11, 2039✓
- January 11, 2039
More about Focinvez (fosaprepitant)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: NK1 receptor antagonists
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
